The brand-new Targeted Radiopharmaceuticals Summit US (TRP US) is the only industry-led meeting dedicated to developing next-generation radioligands. The TRP sector has developed dramatically over the previous 18 months, with a wave of new investment in light of Lutathera’s extraordinary performance.

Are you part of a pharmaceutical business aiming to have their Theranostic approved? If so, this agenda is designed to deliver you a well-rounded and complete understanding of the fast-paced radiopharmaceutical sector while also learning about the critical function of diagnostic imaging.

Hear the latest insights, case studies, and novel data to help accelerate the development of next-generation radioligand therapies from clinical approval to commercialization. This is the only in-person meeting to bring the discussion around the challenges and opportunities facing developers of Theranostic radioligand therapies.

To know more visit: https://ter.li/jtzz4q